by | Apr 10, 2025 | Publications
Hematol Oncol. 2025 May;43(3):e70061. doi: 10.1002/hon.70061. ABSTRACT Daratumumab in combination with lenalidomide and dexamethasone (DRd) and bortezomib in combination with lenalidomide and dexamethasone (VRd) are guideline-recommended preferred regimens for initial...
by | Apr 6, 2025 | Publications
Curr Probl Cancer. 2025 Apr 3;56:101202. doi: 10.1016/j.currproblcancer.2025.101202. Online ahead of print. ABSTRACT BACKGROUND: The efficacy and safety of various therapies for multiple myeloma (MM) remain a subject of ongoing debate, with inconsistent findings. This...
by | Apr 3, 2025 | Publications
Cancer Rep (Hoboken). 2025 Apr;8(4):e70171. doi: 10.1002/cnr2.70171. ABSTRACT BACKGROUND: The treatment landscape for multiple myeloma continues to evolve. Recently, the addition of anti-CD38 monoclonal antibodies (mAbs) to the triplet regimen, comprising a proteasome...
by | Apr 3, 2025 | Publications
Mol Ther. 2025 Mar 31:S1525-0016(25)00222-9. doi: 10.1016/j.ymthe.2025.03.048. Online ahead of print. ABSTRACT Bispecific antibodies (BsAb) are associated with distinct immune-related toxicities that impact morbidity and mortality. This systematic review and...
by | Apr 3, 2025 | Publications
Front Oncol. 2025 Mar 18;15:1517223. doi: 10.3389/fonc.2025.1517223. eCollection 2025. ABSTRACT BACKGROUND: The effect of the controlling nutritional status (CONUT) score on forecasting multiple myeloma (MM) prognosis is previously analyzed, whereas the results...
by | Mar 27, 2025 | Publications
Am J Hematol. 2025 Mar 27. doi: 10.1002/ajh.27661. Online ahead of print. ABSTRACT In the Phase 3 DREAMM-7 study of patients with relapsed/refractory multiple myeloma (RRMM) who received ≥ 1 prior therapy, belantamab mafodotin plus bortezomib and dexamethasone (BVd)...
